phOC-iNOS Vector
Invented by Dr Helen McCarthy at Queen's University Belfast
pCMV-iNOS Vector
Invented by Dr Helen McCarthy from Queen's University Belfast
Invented at Queen's University Belfast
- Datasheet
- References (10)
- Inventor Info
Info
| Catalogue Number | 153287 |
| Bacterial Resistance | Kanamycin |
| Vector Type | pcDNA 3.1 |
| Synonyms | Nitric Oxide Synthase |
| Antigen/Gene or Protein Targets | Inducible Nitric Oxide Synthase |
| Relevance | pCMV-iNOS Plasmid is a human nitric oxide synthase (iNOS) transgene driven by a constitutively active CMV (cytomegalovirus) promoter. Originally developed as an anti-cancer therapeutic with a view to a gene therapy strategies that address hormone refractory prostate cancer (HRPC). Studies in the literature have demonstrated that this plasmid is capable of delaying tumour growth (Adams et al., 2009). The plasmid serves as a useful tool in cardiovascular studies or any physiology associated with vasodilation. |
| Research Area | Cancer, Metabolism, Neurobiology |
| Notes |
Recommended for transpormation in DH5 alpha bacterial cells iNOS gene is 4.4kb |
References: 10 entries
Adams et al. 2009. J Gene Med. 11(2):160-8. PMID: 19062185.
Nitric oxide synthase gene therapy enhances the toxicity of cisplatin in cancer cells.
Europe PMC ID: 19062185
Coulter et al. 2008. Gene Ther. 15(7):495-503. PMID: 18256696.
The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation.
Europe PMC ID: 18256696
McCarthy et al. 2007. J Gene Med. 9(6):511-20. PMID: 17471586.
Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer.
Europe PMC ID: 17471586
McCarthy et al. 2007. Gene Ther. 14(3):246-55. PMID: 17006546.
p21((WAF1))-mediated transcriptional targeting of inducible nitric oxide synthase gene therapy sensitizes tumours to fractionated radiotherapy.
Europe PMC ID: 17006546
Worthington et al. 2002. Gene Ther. 9(4):263-9. PMID: 11896465.
Tumour cell radiosensitization using constitutive (CMV) and radiation inducible (WAF1) promoters to drive the iNOS gene: a novel suicide gene therapy.
Europe PMC ID: 11896465
Add a reference
References: 10 entries
Adams et al. 2009. J Gene Med. 11(2):160-8. PMID: 19062185.
Nitric oxide synthase gene therapy enhances the toxicity of cisplatin in cancer cells.
Coulter et al. 2008. Gene Ther. 15(7):495-503. PMID: 18256696.
The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation.
McCarthy et al. 2007. J Gene Med. 9(6):511-20. PMID: 17471586.
Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer.
McCarthy et al. 2007. Gene Ther. 14(3):246-55. PMID: 17006546.
p21((WAF1))-mediated transcriptional targeting of inducible nitric oxide synthase gene therapy sensitizes tumours to fractionated radiotherapy.
Worthington et al. 2002. Gene Ther. 9(4):263-9. PMID: 11896465.
Tumour cell radiosensitization using constitutive (CMV) and radiation inducible (WAF1) promoters to drive the iNOS gene: a novel suicide gene therapy.
Add a reference
